Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

NCT03402841 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Germline BRCA Mutated Ovarian Cancer

Interventions

DRUG: Olaparib

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]